Bradley J. Monk, MD, FACOG, FACS

Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.

Expert oncologists review the current PARP inhibitor treatment indications for patients with advanced ovarian cancer and discuss how to best manage patients who have been impacted by the recent updates to the PARP inhibitors.

Drs Coleman and Monk discuss what led to the recent withdrawal of several indications for PARP inhibitors in the treatment of advanced ovarian cancer.

Expert oncologists give an overview of PARP inhibitors available for the treatment of patients with advanced ovarian cancer and review adverse events seen with each agent.

Experts on advanced ovarian cancer give detailed insights on the role of biomarker testing and identify important biomarkers.

Robert L Coleman, MD, FACOG, FACS, and Bradley J Monk, MD, FACOG, FACS, provide an overview of advanced ovarian cancer and discuss its prevalence and diagnosis process.

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.

Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.

Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.

Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.

Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.

An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.

Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.

Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.

Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.

Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.

Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.

Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.

Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.

The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.

A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.

Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.

Bradley J. Monk, MD, FACS, FACOG, discusses outcomes with pembrolizumab plus chemotherapy in patients with recurrent or metastatic cervical cancer, as reported in the phase 3 KEYNOTE-826 trial.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Bradley Monk, MD, FACOG, FACS, discusses the mechanism of action of VB-111 in patients with ovarian cancer.